Table 2.
Characteristics of potential TRALI cases, Sentinel Distributed Database (SDD)(n=195)
| n=# of potential inpatient stays with TRALI as defined with inpatient diagnosis codes(n=195) | |
|---|---|
| Sex | |
| Female | 106 (54%) |
| Male | 89 (46%) |
| Unknown | - |
| Age (years) at encounter admission or visit | |
| 0–19 | 10 (5%) |
| 20–34 | 19 (10%) |
| 35–49 | 27 (14%) |
| 50–64 | 45 (23%) |
| 65–79 | 57 (29%) |
| 80+ | 37 (19%) |
| Year of encounter admission | |
| 2013 | 26 (13%) |
| 2014 | 98 (50%) |
| 2015 | 71 (36%) |
| Discharge Disposition | |
| Discharged Alive | 154 (79%) |
| Expired | 41 (21%) |
| Unknown | - |
| Blood component transfused * † | |
| Red Blood Cells (RBCs) any | 153 (78%) |
| Platelets any | 46 (24%) |
| Plasma any | 37 (19%) |
| Cryoprecipitate any | 12 (6%) |
| Unknown or other | 4 (2%) |
| Multiple components | 37(19%) |
| Transfusion indication * † | |
| RBCs | |
| Operative associated blood loss | 26 (13%) |
| Trauma associated blood loss | 9 (5%) |
| Low hemoglobin in patients with heart failure, coronary artery disease, myocardial Infarction, or shock | 20 (10%) |
| Low hemoglobin in patients with syncope or hypotension/orthostatic hypotension not responsive to fluid resuscitation | 6 (3%) |
| Chronic bone marrow failure (myelodysplasia, leukemia) | 27 (14%) |
| Obstetric associated blood loss | 4 (2%) |
| Other: Anemia, low hemoglobin/non-specific | 66 (34%) |
| Platelets | |
| DIC (Sepsis, trauma, obstetrics) | 8 (4%) |
| Immune thrombocytopenia (ITP, neonatal alloimmune thrombocytopenia) | 4 (2%) |
| Disease associated marrow failure (leukemia, lymphoma, aplasia, myeloproliferative/myelodysplastic disorders, solid tumor metastases) | 19 (10%) |
| Chemotherapy/radiation induced marrow failure | 2 (1%) |
| Cardiac surgery associated bleeding | 5 (3%) |
| Bleeding or anticipated surgery in patients on anti-platelet agents | - |
| Trauma- or surgery associated massive transfusion | 8 (4%) |
| Congenital thrombocytopenia/thrombocytopathy | - |
| Other | 11 (6%) |
| Plasma | |
| Abnormal coagulation studies and hemorrhage | 25 (13%) |
| Prophylactic use for elevated PT/APTT | 3 (2%) |
| Warfarin reversal | 3 (2%) |
| Other | 16 (8%) |
| Cryoprecipitate | |
| Fibrinogen deficiency | 7 (4%) |
| Hemophilia A, von Willebrand disease, or F XIII deficiency | - |
| Uremic coagulopathy | 1 (<1%) |
| Other | 12 (6%) |
*
Components listed were abstracted by adjudicators as associated with the potential TRALI event; for 3 patients the exact blood component transfused was not available in the chart because transfusion of interest occurred in a different facility (hospital transfer, or outpatient transfusion); additionally, IVIg was the exposure of interest for 1 patient.
†
Please note, multiple blood components were often administered during a transfusion of interest, and patients also often had multiple indications for transfusion.